The discovery of several chemotherapeutic agents that are active in osteosarcoma has greatly improved the survival compared to the prechemotherapy era. Disease-free survival has escalated from < 20% prior to the introduction of effective chemotherapy to 55–75%. Yet, over the last few decades, we seem to have reached a plateau with respect to further improving the results. The introduction of newer biological agents appears to improve survival but is open to debate. The role of newer imaging modalities, the increasing use of limb salvage with innovative techniques, and closer margins in an attempt to enhance function are avenues that show promise. While these newer developments are exciting, there remain several unanswered questions, which continue to plague us and can be resolved only with increasing data and multi-institutional collaborations. Methotrexate, among the first agents introduced for the treatment of this tumor, has been subjected to intense controversy and scrutiny but appears (finally) to have gained acceptance after 40 years, or has not it? Is it truly mandatory for treatment? Is chemotherapy alteration in poor responders beneficial? What salvage chemotherapy in relapses, and so forth are some of these queries.

We invite researchers and clinicians from all disciplines to contribute original research articles as well as review articles that will shed light on these and other issues in an effort to better understand, treat, and enhance outcomes in osteosarcoma. Potential topics include, but are not limited to:

• Epidemiology
• Biology of osteosarcoma
• Role of newer imaging modalities (for diagnosis, staging, and predicting response to chemotherapy)
• New chemotherapeutic agents
• Targeted tumor therapy, antitumor angiogenesis, and biotherapy
• Surface osteosarcomas
• Secondary osteosarcomas
• Extraskeletal osteosarcomas
• Osteosarcomas in the elderly
• Surgery in osteosarcoma
• Role of radiotherapy
• Salvage therapy
• Palliative care
• Outcome assessment tools and quality of life evaluation

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/srcm/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable: